MKI67 and breast carcinoma: In breast cancer, patients bearing tumours that express high levels of the proliferation marker nuclear antigen Ki67, concomitant with mutations that mitigate apoptotic programmes, exhibit accelerated disease progression and poor prognosis [3]–[6].